KR20220104702A - Raf 키나제의 억제제 - Google Patents

Raf 키나제의 억제제 Download PDF

Info

Publication number
KR20220104702A
KR20220104702A KR1020227016515A KR20227016515A KR20220104702A KR 20220104702 A KR20220104702 A KR 20220104702A KR 1020227016515 A KR1020227016515 A KR 1020227016515A KR 20227016515 A KR20227016515 A KR 20227016515A KR 20220104702 A KR20220104702 A KR 20220104702A
Authority
KR
South Korea
Prior art keywords
optionally substituted
pharmaceutically acceptable
solvate
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227016515A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 더블유 칼도르
투피케 카노우니
존 티호나스
에릭 에이 머피
Original Assignee
킨네이트 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 킨네이트 바이오파마 인크. filed Critical 킨네이트 바이오파마 인크.
Publication of KR20220104702A publication Critical patent/KR20220104702A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227016515A 2019-10-24 2020-10-23 Raf 키나제의 억제제 Pending KR20220104702A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962925596P 2019-10-24 2019-10-24
US62/925,596 2019-10-24
US202063044898P 2020-06-26 2020-06-26
US63/044,898 2020-06-26
PCT/US2020/057132 WO2021081375A1 (en) 2019-10-24 2020-10-23 Inhibitors of raf kinases

Publications (1)

Publication Number Publication Date
KR20220104702A true KR20220104702A (ko) 2022-07-26

Family

ID=75619376

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227016515A Pending KR20220104702A (ko) 2019-10-24 2020-10-23 Raf 키나제의 억제제

Country Status (16)

Country Link
US (3) US11098031B1 (cg-RX-API-DMAC7.html)
EP (1) EP4048259A4 (cg-RX-API-DMAC7.html)
JP (1) JP7626910B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220104702A (cg-RX-API-DMAC7.html)
CN (1) CN114845711B (cg-RX-API-DMAC7.html)
AU (1) AU2020371727B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022007612A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158530A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000998A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022006712A2 (cg-RX-API-DMAC7.html)
IL (1) IL292424B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022004937A (cg-RX-API-DMAC7.html)
PH (1) PH12022550976A1 (cg-RX-API-DMAC7.html)
TW (1) TWI899110B (cg-RX-API-DMAC7.html)
WO (1) WO2021081375A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204284B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114072148A (zh) 2019-05-03 2022-02-18 金耐特生物制药公司 Raf激酶的抑制剂
AU2020371727B2 (en) * 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
US20230046018A1 (en) * 2019-12-06 2023-02-16 Medshine Discovery Inc. Biaryl compound as pan-raf kinase inhibitor
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2022060996A1 (en) * 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP7825636B2 (ja) * 2021-04-23 2026-03-06 ピエール ファーブル メディカモン (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
TW202308645A (zh) * 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療
US20240327343A1 (en) * 2021-07-19 2024-10-03 Kinnate Biopharma Inc. Preparation method of 3- (2, 2, 2-trifluoroethyl) pyrrolidine hydrochloride
CN115974851A (zh) * 2021-10-14 2023-04-18 华领医药技术(上海)有限公司 2-氧代-3-氮杂双环[3.1.0]己烷衍生物
WO2023070053A1 (en) * 2021-10-21 2023-04-27 Kinnate Biopharma Inc. Inhibitors of raf kinases
AU2022405115A1 (en) * 2021-12-09 2024-07-11 Deciphera Pharmaceuticals, Llc Raf kinase inhibitors and methods of use thereof
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof
TW202342055A (zh) 2022-02-03 2023-11-01 美商奇奈特生物製藥公司 Raf激酶抑制劑
US20250171462A1 (en) * 2022-03-02 2025-05-29 Nico Therapeutics, Inc. Compounds, compositions, and methods
US20260100247A1 (en) * 2022-09-30 2026-04-09 Foundation Medicine, Inc. Systems and methods for processing clinico-genomic data

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2592118C (en) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
EP2252612B1 (en) 2008-02-22 2012-03-28 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なヘテロアリール化合物
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
KR101652229B1 (ko) 2012-06-07 2016-08-30 데시페라 파마슈티칼스, 엘엘씨. 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
ES2844211T3 (es) 2014-09-12 2021-07-21 Novartis Ag Compuestos y composiciones en calidad de inhibidores de quinasa
UY36294A (es) * 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
JP6636014B2 (ja) * 2014-09-12 2020-01-29 ノバルティス アーゲー Rafキナーゼ阻害剤としての化合物および組成物
BR112018075371A2 (pt) 2016-06-10 2019-03-19 Novartis Ag usos terapêuticos de um inibidor de c-raf
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2020168172A1 (en) 2019-02-15 2020-08-20 Zamboni Chem Solutions Inc. Conjugate compounds for the degradation of raf
JP2022525885A (ja) * 2019-03-22 2022-05-20 キネート バイオファーマ インク. Rafキナーゼの阻害剤
CN114072148A (zh) 2019-05-03 2022-02-18 金耐特生物制药公司 Raf激酶的抑制剂
AU2020371727B2 (en) 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP7825636B2 (ja) 2021-04-23 2026-03-06 ピエール ファーブル メディカモン (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
TW202308645A (zh) 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療

Also Published As

Publication number Publication date
MX2022004937A (es) 2022-07-27
US11098031B1 (en) 2021-08-24
EP4048259A1 (en) 2022-08-31
EP4048259A4 (en) 2023-08-02
AU2020371727B2 (en) 2026-01-22
JP7626910B2 (ja) 2025-02-05
US20260055084A1 (en) 2026-02-26
TW202128680A (zh) 2021-08-01
CA3158530A1 (en) 2021-04-29
BR112022007612A2 (pt) 2022-09-20
PH12022550976A1 (en) 2023-09-25
IL292424B2 (en) 2026-06-01
NZ788005A (en) 2024-10-25
IL292424B1 (en) 2026-02-01
CN114845711A (zh) 2022-08-02
TWI899110B (zh) 2025-10-01
IL292424A (en) 2022-06-01
CO2022006712A2 (es) 2022-05-31
JP2022554169A (ja) 2022-12-28
CL2022000998A1 (es) 2023-02-10
ZA202204284B (en) 2024-09-25
US12312336B2 (en) 2025-05-27
WO2021081375A1 (en) 2021-04-29
AU2020371727A1 (en) 2022-05-26
US20210300904A1 (en) 2021-09-30
CN114845711B (zh) 2024-10-01

Similar Documents

Publication Publication Date Title
US12312336B2 (en) Inhibitors of RAF kinases
CN116888108B (zh) 新型egfr降解剂
US20240025902A1 (en) Bifunctional compounds for degradation of egfr and related methods of use
KR20210040368A (ko) 사이클린 의존성 키나제의 억제제
EP3442947A1 (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
WO2020198058A1 (en) Inhibitors of raf kinases
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
US12122761B2 (en) 2-azaspiro[3.4]octane derivatives as M4 agonists
WO2018137618A1 (en) Compounds for inhibiting lrrk2 kinase activity
WO2024102621A1 (en) Akt1 modulators
BR112020010012A2 (pt) compostos de pirazolopiridinona
EP3573980A1 (en) Compounds
HK40077347A (zh) Raf激酶的抑制剂
WO2025076088A1 (en) Lactams for use as sarm1 inhibitors
HK40063842A (en) Inhibitors of raf kinases
TW202233624A (zh) Btk抑制劑
HK40077347B (en) Inhibitors of raf kinases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701